MedTrace Logo

Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease

NCT01841905 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2016-01-20

No results posted yet for this study

Summary

The investigators are conducting a study to try to improve our ability to identify older adults who are at high-risk for progression to Alzheimer's disease, several years before they have symptoms that might reduce their quality of life. The investigators believe they can increase the sensitivity of tests of memory and problem solving, by using a very small dose of a medication (scopolamine) that reduces the activity of the principal chemical system in the brain that is changing in the earliest stages of Alzheimer's disease. By pairing this "micro-dose" drug challenge (that is administered with a tiny needle placed just under the surface of the skin on the forearm), with our tests of memory and thinking, it is believed that the investigators can create a "stress test" that is very similar in concept to the use of the exercise treadmill to make the results of a heart EKG more sensitive to detect early disease, as a cardiac stress test for heart disease. The investigators want to create a similar stress test for Alzheimer's disease (AD).

Conditions

Interventions

OTHER

Observational Study

Observational Study

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Heidelberg Engineering, Inc.

    collaborator UNKNOWN

  • Neurotrack

    collaborator UNKNOWN

  • Optovue

    collaborator INDUSTRY

  • Avid Pharmaceuticals

    collaborator UNKNOWN

  • Rhode Island Hospital

    lead OTHER

Principal Investigators

  • Peter J. Snyder, Ph.D. · Sr. Vice President & Chief Research Officer, Lifespan

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01841905 on ClinicalTrials.gov